1. Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934–1943PMID : 12675874.
2. Prado M, Roa LM, Palma A, Milan JA. Double target comparison of blood-side methods for measuring the hemodialysis dose. Kidney Int 2005;68:2863–2876PMID : 16316364.
3. Vienken J, Bowry S. Quo vadis dialysis membrane? Artif Organs 2002;26:152–159PMID : 11879244.
4. Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci 2004;41:467–550PMID : 15603510.
5. Rule AD, Bergstralh EJ, Slezak JM, Bergert J, Larson TS. Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int 2006;69:399–405PMID : 16408133.
6. Shlipak MG, Praught ML, Sarnak MJ. Update on cystatin C: new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens 2006;15:270–275PMID : 16609294.
7. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004;65:1416–1421PMID : 15086483.
8. Mojiminiyi OA, Abdella N. Evaluation of cystatin C and beta-2 microglobulin as markers of renal function in patients with type 2 diabetes mellitus. J Diabetes Complications 2003;17:160–168PMID : 12738401.
9. Campo A, Lanfranco G, Gramaglia L, Goia F, Cottino R, Giusto V. Could plasma cystatin C be useful as a marker of hemodialysis low molecular weight proteins removal? Nephron Clin Pract 2004;98:c79–c82PMID : 15528941.
10. Thysell H, Grubb A, Lindholm T, Ljunggren L, Martensson L. Cystain C: a new marker of biocompatibility or a good marker for the redistribution of LMW proteins during hemodialysis? ASAIO Trans 1988;34:202–204PMID : 3058174.
11. Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006;48(Suppl 1):S2–S90PMID : 16813990.
12. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993;4:1205–1213PMID : 8305648.
13. Diaz-Buxo JA, Loredo JP. Standard Kt/V: comparison of calculation methods. Artif Organs 2006;30:178–185PMID : 16480392.
14. Cheung AK, Levin NW, Greene T, et al. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol 2003;14:3251–3263PMID : 14638924.
15. Ayli D, Ayli M, Azak A, et al. The effect of high-flux hemodialysis on renal anemia. J Nephrol 2004;17:701–706PMID : 15593038.
16. Vanholder R, Glorieux G, De Smet R, Lameire N. New insights in uremic toxins. Kidney Int Suppl 2003;(84):S6–S10PMID : 12694297.
17. Basile C. The effect of convection on the nutritional status of haemodialysis patients. Nephrol Dial Transplant 2003;18(Suppl 7):vii46–vii49PMID : 12953030.
18. Leypoldt JK, Cheung AK. Removal of high-molecular-weight solutes during high-efficiency and high-flux haemodialysis. Nephrol Dial Transplant 1996;11:329–335PMID : 8671788.
19. Clark WR, Gao D. Determinants of uraemic toxin removal. Nephrol Dial Transplant 2002;17(Suppl 3):30–34PMID : 11912297.
20. Locatelli F, Manzoni C, Di Filippo S. The importance of convective transport. Kidney Int Suppl 2002;(80):115–120PMID : 11982825.
21. Lindsay RM, Henderson LW. Adequacy of dialysis. Kidney Int Suppl 1988;24:S92–S99PMID : 3283413.
22. Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y. Superior dialytic clearance of beta(2)-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int 2006;70:794–799PMID : 16820785.
23. Ayli M, Ayli D, Azak A, et al. The effect of high-flux hemodialysis on dialysis-associated amyloidosis. Ren Fail 2005;27:31–34PMID : 15717632.
24. Locatelli F, Andrulli S, Pecchini F, et al. Effect of high-flux dialysis on the anaemia of haemodialysis patients. Nephrol Dial Transplant 2000;15:1399–1409PMID : 10978398.
25. Leypoldt JK, Cheung AK, Deeter RB. Rebound kinetics of beta2-microglobulin after hemodialysis. Kidney Int 1999;56:1571–1577PMID : 10504510.
26. Ward RA, Greene T, Hartmann B, Samtleben W. Resistance to intercompartmental mass transfer limits beta2-microglobulin removal by post-dilution hemodiafiltration. Kidney Int 2006;69:1431–1437PMID : 16395268.
27. Newman DJ. Cystatin C. Ann Clin Biochem 2002;39(Pt 2):89–104PMID : 11928770.
28. Levy E, Jaskolski M, Grubb A. The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models. Brain Pathol 2006;16:60–70PMID : 16612983.
29. Reed CH. Diagnostic applications of cystatin C. Br J Biomed Sci 2000;57:323–329PMID : 11204865.
30. Revesz T, Ghiso J, Lashley T, et al. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 2003;62:885–898PMID : 14533778.
32. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006;145:237–246PMID : 16908914.